Navigation Links
Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
Date:11/7/2011

ncluding the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.ALEXZA PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Revenue

$
,259$
744$
3,776$
744Operating expenses:Research and development

8,0516,65420,97722,508General and administrative

3,1092,6108,66411,474Total operating expenses

11,1609,26429,64133,982Loss from operations

(9,901)(8,520)(25,865)(33,238)Loss on change in fair value of contingent consideration liability

(3,000)8,509(3,300)7,338Interest and other income/ (expense), net

13193028Interest expense

(529)(599)(1,703)(1,024)Net loss

'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
3. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
4. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
5. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
6. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
8. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
9. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
10. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
11. Alexza to Present at the MDB Bright Lights Conference 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ) ... and managing director of Warburg Pincus LLC, to the Amgen ... welcome Fred Hassan and the deep, global experience ... said Robert A. Bradway , chairman and chief executive ... innovation will serve Amgen well." Mr. Hassan has ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... NOVATO, Calif., Aug. 13 BioMarin,Pharmaceutical Inc. (Nasdaq ... the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3,clinical trial ... of The Lancet.,The study suggests that treatment with ... in some phenylketonuria (PKU) patients.,Kuvan, an investigational oral ...
... Aug. 13 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ... oral presentation at the American Chemical Society National,Meeting ... 21, 2007,at 2:50 p.m. Eastern Time. The presentation, ... levels by enzyme inhibitors for the,potential treatment of ...
Cached Medicine Technology:Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 2Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 3Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 4Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet 5Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 2Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 3
(Date:8/1/2015)... ... , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has ... business donation to kick off the campaign for healing and Well-Being. , BeverlyD has ... complete line of raw, organic hair care products, as well as her book, Hair ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and warm-season turfgrasses, ... of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, ... of this new type of sod, Super-Sod is giving away red Adirondack chairs with ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 ... Pasadena courthouse was contained and extinguished by the city’s fire department before it caused major ... at the time of the fire, and it was a fire alarm system that tipped ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... Research Group is,an exciting newcomer in the field ... information service established to,provide the general public with ... choose for a variety of medical problems resulting ... the website will be,obtained through an online survey ...
... of the,Board and Chief Executive Officer, A.G. Lafley, addressed ... at its annual meeting today. Lafley,said, "P&G is a ... long term,-- consistently, reliably and sustainably." Growth in ... fiscal 2007. P&G increased,net sales by 12 percent to ...
... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
... Nutrition,(OTC Bulletin Board: NNTN) http://www.interactivenutrition.com will ... 2007 at,11:00 a.m. Eastern time. U.S. and Canadian ... 800-750-4065 and International Shareholders may dial in at,404-920- ... 767872#. Executives,from Natural Nutrition will be available for ...
... Exchange Symbol: AKL, MONTREAL, Oct. 9 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation, pain ... 2007, its issued and outstanding common shares will ... common share for every seven (7),pre-consolidation common shares. ...
Cached Medicine News:Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Natural Nutrition to Hold International Shareholder Conference Call Thursday, October 11, 2007 at 11:00 a.m. Eastern Time 2Health News:Akela Pharma Inc. Completes Share Consolidation 2
For use with catalog #0454....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Free Protein S, ELISA Method...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Medicine Products: